AstraZeneca plans to directly list its ordinary shares on the New York Stock Exchange to attract global investors, replacing its existing US listing of American Depositary Receipts on Nasdaq. This move aims to harmonize its listing structure while remaining headquartered in the UK. Analysts suggest this could hint at a future shift away from the London Stock Exchange. Teljes cikk (Euronews.com)